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Background: To evaluate in-hospital and long-term mortality of patients with acute coronary
syndromes (ACS) not having selective coronary angiography (CAG) during hospitalization
and to analyze the reasons for conservative approach.
Methods and patients: A single-centre retrospective study using registry data. Over the period
from January 2005 to April 2009, a total of 193 ACS patients did not have in-hospital CAG.
Fifty-ﬁve (28.5%) patients had recent CAG (within the last 12 months) or the procedure was
planned after discharge (invasive group ‘‘I’’). In 138 (71.5%) patients, CAG was not considered
at all (conservative approach, group ‘‘C’’). These subgroups were compared in terms of in-
hospital parameters and long-term mortality.
Results: ST-segment elevation myocardial infarction (STEMI) was diagnosed in 50 (25.9%)
patients. The most frequent reasons for not performing CAG included serious comorbidities
affecting the prognosis (22%) and pharmacological stabilization in very old individuals with
non-STEMI (21%). One in ten (11%) patients died before the CAG was performed, the same
proportion of patients refused to have CAG or had a long ischaemia time (STEMI subgroup). A
temporary contraindication to CAG was found in 8%, a recent CAG ﬁnding not suitable for
revascularization in 8%, while a limiting neurological disease was present in 6% of patients.
In-hospital mortality was 30.1%, being higher in Group C (34.1% vs. 20.0%; p = 0.049), 6-year
mortality was as high as 78.8%, also with higher rates in Group C (86.2% vs. 60.2%; p < 0.001).
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tion; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass
grafting; AHEADACS, Acute HEArt failure Database – Acute Coronary Syndromes; AHF, acute heart failure; IKK FN Brno, Department of
Cardiology and Internal Medicine, University Hospital Brno (Interní kardiologická klinika Fakultní nemocnice Brno); MI, myocardial
infarction; UA, unstable angina; BMI, body mass index; LV, left ventricle; ECG, electrocardiography.
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Patients receiving conservative therapy were older, with a higher proportion of limiting
comorbidities that contraindicated CAG, and had a more serious course of hospitalization.
Conclusion: The most common reasons for not performing CAG in ACS patients included
advanced age, serious and often extra-cardiac comorbidities, and a complicated hospitali-
zation course. The short- and long-term mortality rates in these patients are high.
# 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp. z o.o.
All rights reserved.
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.Introduction
Selective coronary angiography (CAG) followed by myocardial
revascularization using percutaneous coronary intervention
(PCI) or coronary artery bypass grafting (CABG) is considered as
the optimal procedure in the treatment of acute coronary
syndromes (ACS). The superiority of the invasive approach
over pharmacological reperfusion with thrombolysis or,
alternatively, conservative treatment has been documented
both for the population of patients with ST-segment elevation
myocardial infarction (STEMI) [1] and non-ST-segment eleva-
tion myocardial infarction (NSTEMI) [2]. However, there is a
small patient population who do not undergo CAG at all (and
treated conservatively), or assessment of their coronary
arteries is scheduled later after discharge. The proﬁle of these
patients and their long-term prognosis have not been fully
characterized yet.
The aim of our study was to characterize patients with the
diagnosis of ACS admitted to a cardiology-specialized  univer-
sity tertiary centre who are primarily indicated – despite the
immediate availability of angiographic assessment – for
conservative treatment, with only pharmacotherapy. The
study examines the main reasons of not performing CAG.
Within this population, groups of patients with a recent
angiogram available (CAG performed within the last 12
months before the admission for ACS) or with planned CAG
after discharge (i.e., CAG considered as necessary) are
compared with those not primarily indicated for the procedure
at all. Both in-hospital and long-term mortality data will also
be analyzed.
Methods
Data analyzed in this study were obtained from the AHEAD-
ACS (Acute HEArt failure Database – Acute Coronary Syn-
dromes) registry. This multi-centric registry of acute heart
failure (AHEAD) was created in 2005 with an effort to
investigate the epidemiology, treatment, and prognosis of
patients with acute heart failure (AHF) of all aetiologies in
Czech Republic, and had a prospective design [3]. Since 2008,
the registry has been systematically complemented with data
in a retrospective manner to include ACS patients irrespective
of the presence of AHF in the largest centre – the Department
of Cardiology an Internal Medicine of University Hospital Brno
(IKK FN Brno). The purpose of this sub-registry is to evaluate
the incidence and effect of AHF in ACS and to establish the
long-term prognosis of this patient population (the registrycontains long-term mortality data). Data are being collected in
a consecutive manner.
The following inclusion criteria were selected for the study:
ﬁrst hospitalization for ACS at IKK FN Brno from 1 January 2005
through 30 June 2008, and hospitalization without performing
CAG. The dataset comprises a total of 193 patients. At an
average number of 55 patients hospitalized in our centre per
month, this number represents about 8% of the total
population diagnosed to have ACS. Our study compares the
part of this population not indicated for CAG at all (referred to
as Group ‘‘C’’ hereinafter; N = 138) with those patients
undergoing CAG recently prior to hospital admission (i.e.,
performed within the last 12 months but with ﬁndings not
suitable for revascularization) and/or patients considered for
an elective procedure after the discharge, most often with a
temporary contraindication for CAG during hospitalization
(referred to as group ‘‘I’’ hereinafter; N = 55).
The parameters compared in the study included data
related to the patients' medical history, examinations per-
formed during hospitalization, and treatment (long-term and
in-hospital). In addition, the comparison included analysis of
total in-hospital and long-term mortality. The follow-up
period ranged from 0 to 92 months (with 23 months being
the average), and 5 months of median follow-up time. Total
mortality data were obtained from the Institute of Health Care
Information and Statistics of the Czech Republic (Prague).
Patients whose data had been entered into the registry signed
their informed consent, the registry protocol was approved by
Ethics Committee of the University Hospital Brno, and data
collection was made in compliance with the Declaration of
Helsinki.
Statistical analysis
Dataset analysis was performed using basic descriptive
statistics; because of data asymmetry, median and 5th and
95th percentiles are given for continuous variables, with the
proportions of individual categorical variables described by
their frequency and percentage counts.
Comparison of patient groups by elective CAG and
availability of angiographic ﬁnding was performed using the
chi-square test for categorical variables, and the Mann–
Whitney test for continuous variables. Cumulative mortality
curves were assessed using the Kaplan–Meier estimate of
survival function, with the individual curves compared using
the log rank test. A difference at a level of signiﬁcance of
a = 0.05 was considered statistically signiﬁcant.
The analysis was performed using IBM SPSS Statistics 21 for
Windows software (Release 21.0.0, # IBM Corporation 2012)
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2011 The R Foundation for Statistical Computing] using a
Thomas Lumley (2011) survival package: Survival analysis,
including penalized likelihood.
Results
Of the total of 193 patients, CAG was scheduled (after
discharge) or their recent CAG ﬁnding was available in 55
(28.5%) patients. The mean age of the whole study population
was 80 years (range, 52–91), with 77.7% aged over 70 years, and
49.7% aged over 80 years. Patients not indicated for CAG were
older [81 (range, 52–93) vs. 76 years (range, 52–86), p = 0.003].
Males were present in 54.4% of the whole group (N = 105) with a
higher proportion in Group I (74.5% vs. 46.4%; p < 0.001).
In the whole study population, a baseline diagnosis of
STEMI was established in 50 (25.9%) patients, with a higher
proportion in Group C (31.2% vs. 14.5%; p = 0.014). At discharge,
the ﬁnal diagnosis of Q-wave myocardial infarction (MI) was
established in 34.1% of patients, again with a higher proportion
in Group C (42.1% vs. 18.6%; p = 0.014). Non-Q-MI was
diagnosed in 49.3% of patients while 16.7% of patients had
unstable angina (UA) with negative cardiac enzymes.
Reasons for conservative approach
Within the whole group of our patients, we identiﬁed eight
main reasons why physicians chose conservative treatment
without performing CAG during hospitalization. TheseDelay
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Fig. 1 – Causes of conservative approachreasons are shown in Fig. 1. The most frequent were serious
comorbidities and pharmacological stabilization in very old
patients diagnosed to have NSTEMI on admission. One in 10
patients died before CAG could have been performed (mostly
immediately after hospital admission, 9.1% of such patients
were present in Group I). Among patients receiving primarily
conservative treatment a markedly higher proportion of
those with prognosis-limiting comorbidities was found
(29.7% vs. 3.6% in Group I); there was also a difference in
the incidence of patients presenting already in the sub-acute
phase of STEMI (15.4% vs. 1.8% in the Group I). Conversely,
patients planned for elective CAG, had more often a
temporary reason for not undergoing the procedure during
the index hospitalization (18.2% infectious disease vs. 2.2% in
Group C).
Hospitalization course
Patients considered to undergo CAG had a higher baseline
body mass index (BMI) and blood pressure on admission, with
suspected ischaemia more often affecting the anterior wall of
the left ventricle (LV). On the other hand, patients with
conservative approach had a higher incidence of impaired
consciousness at admission (Table 1). Patients considered for
CAG had more often myocardial revascularization procedures
in the past as well as higher long-term use of beta-blockers and
lipid-lowering drugs before the hospital admission (Table 2).
A total of 40.6% of patients had echocardiography-
documented LV ejection fraction (LVEF) < 40% (moderate LV
systolic dysfunction), with a higher average LVEF found inComorbidies  aﬀecng 
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Table 1 – Clinical assessment at admission and suspected ACS location (ECG, echocardiography).
Parameter N (%)/median (5th; 95th percentiles) p
Total (N = 193) Group C (N = 138) Group I (N = 55)
BMI 26.8(20.8; 38.0) 25.4(20.2; 38.0) 28.4(22.2; 35.4) 0.044
Admission systolic BP (mmHg) 140(80; 210) 130(70; 205) 145(90; 230) 0.004
Admission systolic BP < 100 mmHg 17.2% 20.4% 9.1% 0.047
Admission diastolic BP 75(45; 110) 70(40; 110) 80(50; 130) 0.068
Baseline heart rate (b.p.m.) 93(54; 133) 95(50; 135) 88(55; 120) 0.073
Atrial ﬁbrillation/ﬂutter (ECG) 19.7% 21.7% 14.5% 0.070
QRS ≥ 120 ms (admission ECG) 21.4% 23.8% 15.0% 0.235
Impaired consciousness on admission 14.5% 18.8% 3.6% 0.003
Pre-hospital cardiac arrest 2.6% 3.6% 0.0% 0.064
ACS location
Inferior wall 18.5% 22.4% 9.4% 0.024
Lateral wall 6.2% 6.4% 5.7%
Anterior wall 42.1% 35.2% 58.5%
Unclear 33.1% 36.0% 26.4%
BMI, body mass index; BP, blood pressure; ECG, electrocardiography; ACS, acute coronary syndrome. P-values below 0.05 are taken as
statistically signiﬁcant.
Table 2 – Personal history and previous chronic treatment.
Parameter N (%)/median (5th; 95th percentiles) p
Total (N = 193) Group C (N = 138) Group I (N = 55)
Hypertension 79.9% 80.7% 77.8% 0.649
Hyperlipidaemia 68.3% 66.3% 73.0% 0.462
Diabetes mellitus 49.7% 52.6% 42.6% 0.214
History of myocardial infarction 43.9% 40.0% 53.7% 0.087
Previous PCI and/or CABG 13.2% 8.9% 24.1% 0.008
History of stroke/TIA 23.3% 26.7% 14.8% 0.072
Peripheral arterial disease 12.7% 8.9% 22.2% 0.017
Chronic obstructive pulmonary disease 14.3% 14.1% 14.8% 0.896
Smoking 21.7% 20.4% 24.4% 0.289
History of malignancy 11.9% 13.0% 9.0% 0.433
Class III/IV (NYHA) dyspnoea 10.2% 9.0% 13.0% 0.429
Class III/IV (CCS) angina 6.2% 4.3% 10.9% 0.104
Long-term therapy before hospitalization
Antiplatelet drugs 63.1% 61.1% 67.9% 0.385
RAAS blockers 60.9% 61.1% 60.4% 0.927
Beta-blockers 42.5% 37.3% 54.7% 0.032
Lipid-lowering drugs 23.3% 17.4% 38.2% 0.003
Oral nitrates 37.4% 34.9% 43.4% 0.287
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; TIA, transient ischaemic attack; NYHA, New York Heart
Association classiﬁcation; CCS, Canadian Cardiovascular Society classiﬁcation; RAAS, renin-angiotensin-aldosterone system. P-values below
0.05 are taken as statistically signiﬁcant.
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acute heart failure and or haemodynamic instability (mani-
fested as hypotension requiring vasoactive treatment). De-
spite similar baseline creatinine levels, conservatively treated
patients were more often diagnosed to have acute renal injury
during hospitalization (Table 3). This patient population had
signiﬁcantly higher GRACE scores (176 vs. 144 points;
p < 0.001), with 8 patients experiencing severe in-hospital
bleeding (5.8% of Group C).
Mortality
The difference in overall mortality in selected subgroups
became evident already during hospitalization. Total in-
hospital and 30-day mortality rates were 30.1% and 36.3%,respectively, with signiﬁcantly poorer outcome in conserva-
tively treated patients [in-hospital mortality of 34.1% vs. 20.0%
( p = 0.049) and 30-day mortality of 42.8% vs. 20% ( p = 0.002)].
Long-term mortality rates are shown in Fig. 2. There were up to
86.2% of deaths observed in the population of patients not
undergoing CAG over a period of 6 years; on the other hand 6-
year mortality in the invasively treated group was 60.2%
( p < 0.001).
Discussion
Only less than one tenth of patients admitted for ACS to the
tertiary university centre with 24-h PCI service do not have in-
hospital CAG, and over two thirds of these patients are not
Table 3 – Hospitalization course.
Parameter N (%)/median (5th; 95th percentiles) p
Total (N = 193) Group C (N = 138) Group I (N = 55)
LVEF (echocardiography) 40.0(20.0; 65.0) 40.0(20.0; 62.0) 47.0(25.0; 65.0) 0.023
Signs of acute heart failure 73.6% 78.3% 61.8% 0.029
Lung oedema (chest X-ray) 18.1% 21.0% 10.9% 0.033
Pleural effusion (chest X-ray) 29.4% 31.7% 22.9% 0.315
Cardiogenic shock 28.0% 32.6% 16.4% 0.019
Mechanical pulmonary ventilation 25.9% 29.7% 16.4% 0.049
Hypotension requiring treatment 19.2% 9.4% 43.6% <0.001
In-hospital infection/sepsis 48.7% 51.4% 41.8% 0.226
Laboratory assessment
Baseline haemoglobin (g/L) 127(91; 158) 126(89; 157) 130(99; 159) 0.209
Uric acid (mmol/L) 400(232; 709) 418(202; 800) 344(250; 663) 0.074
Baseline creatinine (mmol/L) 117(71; 266) 117(73; 283) 115(70; 259) 0.989
Maximal creatinine (mmol/L) 130(73; 462) 138(76; 506) 119(70; 393) 0.028
Acute kidney injury (AKI) 33.2% 39.1% 18.2% 0.004
In-hospital intravenous treatment
Noradrenaline/adrenaline 31.6% 37.7% 16.4% 0.003
Dobutamine/levosimendan 22.3% 27.5% 9.1% 0.003
Nitrates 31.6% 29.7% 36.4% 0.373
Diuretics 65.3% 71.7% 49.1% 0.003
Antibiotics 49.2% 54.4% 36.5% 0.030
Treatment at discharge in surviving patients
Antiplatelet drugs 92.6% 90.1% 97.7% 0.082
RAAS blockers 80.7% 80.2% 81.8% 0.825
Beta-blockers 81.5% 78.0% 88.6% 0.124
Lipid-lowering drugs 77.8% 73.6% 86.4% 0.085
Oral nitrates 47.4% 41.8% 59.1% 0.058
LVEF, left ventricular ejection fraction; AKI, acute kidney injury – deﬁned as the difference between peak and baseline serum creatinine ≥ 26 (AKI 1)
or peak creatinine/baseline creatinine ratio of ≥2 or need for acute haemodialysis (AKI 2). P-values below 0.05 are taken as statistically signiﬁcant.
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conservative, pharmacological therapy. Taking account of the
well-organized network of PCI and non-PCI hospitals within
the Czech Republic, this is a relatively small proportion of0.0
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undertaken in one out of 10 STEMI patients and in more than
one in four patients with the diagnosis of NSTEMI [4]. However,
the number of ACS patients undergoing CAG in the Czech
Republic is above the European average in general [5,6].
The most frequent reasons why CAG is not performed are
serious comorbidities adversely affecting the prognosis and/or
multi-morbidity of patients. Almost 50% of patients in our
cohort had diabetes mellitus, similarly a history of MI and
anaemia documented by laboratory investigations (45.9%), and
more than two thirds had renal failure with a creatinine
clearance < 60 ml/min (70.5%). About 10% of our patients had a
history of cancer. Signs of an infectious disease were detected
in 50% of our patients during hospitalization, while a third
experienced signiﬁcant deterioration of renal function.
Current guidelines for myocardial revascularization recom-
mend CAG in all ACS patients. In the subgroup of STEMI
patients, the decision to indicate the procedure is based on the
assumed ischaemia time [7]. About one half (44.9%) of our STEMI
patients did not have CAG because of a long ischaemia time.
Another reason was death before the procedure (26.5% of STEMI
patients). A tenth of our patients refused to have CAG. It should
be emphasized a high mean age (80 years) of our population,
which is more frequently associated with atypical symptom-
atology (absence of angina) as well as relatively poor mobility.
In NSTEMI patients, timing of CAG is dependent on the
patient's risk stratiﬁcation [8]. An initially conservative
approach is possible in two subgroups of patients. The ﬁrst
one comprises so called low-risk patients, who are younger,
hemodynamically stable individuals without the risk factors of
coronary heart disease, with no ECG abnormalities, with
negative values of cardiac markers and a early exercise testing
without signs of ischaemia. These criteria were met by only
ﬁve patients of our population. Three patients were planned
for CAG at a later time because of acute infection and two
patients refused to have the examination. Another subgroup
of NSTEMI patients, initially not suitable for an invasive
strategy, are patients with excessively high risk associated
with invasive procedure or intervention. These are especially
individuals with advanced age and serious comorbidities
affecting their life expectancy and quality of life that are also
increasing the risk of ischaemic and bleeding complications.
Advanced age is generally associated with a higher risk of
adverse effects of therapeutic interventions. These may
especially include bleeding due to antiplatelet and antic-
oagulation therapy, whose rates could be reduced in the future
by the increasing intention to use a radial approach when
performing CAG. Another possible complication during inva-
sive procedures in older patients are hypotension, tachycardia
as a signs of circulatory failure and contrast-induced acute
kidney injury. In our group, signs of renal impairment were
seen already at admission in 70.5% of patients, with renal
function deteriorating during hospitalization (even without
use of contrast agents) in a third.
The overall high risk proﬁle of our study cohort is conﬁrmed
by the average GRACE score (168 points). Although an early
invasive approach (within 24 h) in patients with a GRACE
score > 140 in the TIMACS trial was associated with a 38%
reduction of death, MI or stroke at 6 months, there is no doubt
that a selective approach is used in clinical practice and thathigher age with multiple comorbidities are seen as major
limitations of CAG [9]. This is also supported by the fact that, in
some studies, patients indicated for CAG paradoxically had
GRACE scores lower than those treated conservatively. This
inverse relation between the risk proﬁle and the use of
invasive approach was also observed in our study [10,11]. The
higher mortality rates in patients not indicated for CAG can be
associated with overall worse health status of this population
whose outcome depends on the presence of another, often
extra-cardiac, comorbidities.
Given the advanced age and risk proﬁle of our study
population, the relatively high in-hospital and long-term
mortality rates are not unexpected. In the study by Terkelsen
et al., the in-hospital mortality of patients with a mean age of
80 years and ACS with bundle branch block was 33.3%, with
one-year mortality being as high as 54.8% [12]. In another study
by Belgian authors, the in-hospital mortality rate in STEMI
patients aged over 80 years was 17.8%; however, in patients
with signs of heart failure, it was markedly high regardless of
the therapeutic strategy (PCI subgroup 34.6%, patients treated
with thrombolysis 31.6%, conservative approach 36.3%;
p = 0.88) [13].
Limitations
The study was conducted in a single university centre
specialized in cardiology admitting only a small proportion
of unselected internal medicine patients, thus does not exactly
reﬂects the epidemiological status of ACS patients receiving
conservative treatment. A more accurate estimate of the
numbers of these patients could be obtained in departments of
internal medicine of regional hospitals with exclusively
unselected hospital admissions. However, the study identiﬁes
reasons of conservative approach without performing CAG
despite its immediate availability. Because of the retrospective
nature of the data capture, we cannot exclude, that some of the
patients could undergo CAG in the future. Furthermore, the
study documented a relatively high proportion of patients
experiencing in-hospital acute heart failure. As the data were
extracted predominantly from an acute heart failure registry,
we cannot rule out that, in some cases, the diagnosis may have
been established mainly on the basis of elevated cardiac
enzymes associated with acute heart failure per se. This fact
may have resulted in an overlap of the diagnoses.
Conclusion
Only a small proportion of patients admitted to a specialized
cardiac university centre for ACS do not undergo invasive
examination of coronary arteries despite its immediate
availability. Over two thirds of these patients are not indicated
for coronary angiography even in the future and after the
elimination of relative contraindication for the procedure (e.g.,
bleeding or infective disease). This population is characterized
by advanced age, multiple comorbidities, and a complicated
hospitalization course and probably will not beneﬁt from an
invasive approach. Their outcome is frequently related to
another, often extra-cardiac disease. The short- and long-term
mortality rates of these patients are high.
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